Listen now: podcast Susan O’Brien about the value of acalabrutinib in CLL

September 2021 Podcasts Eline Feenstra

In this episode, Prof. Susan O’Brien (University of California Irvine, United States) discusses the value of acalabrutinib in chronic lymphocytic leukemia (CLL), in light of the recently published data of a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated CLL patients. As one of the principal investigators of the ELEVATE-RR study, she will first dig deeper into the results of this pivotal trial and afterwards shares her views on the potential added value of acalabrutinib in the daily management of patients with CLL.

Click here to listen to the podcast

X